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Abstract
Background: The aim was to examine the correlation of early follicular serum lutinising hormone
(LH) and the clinical outcome of assisted reproduction technique (ART).
Methods:  An observational study included 1333 consecutive women undergoing invitro
fertilization (IVF) and intracytoplasmic sperm injection (ICSI). 964 women were having their first
cycle of ART. Data were entered prospectively. All women had serum LH measured in the 6
months before the index cycle studied. No repeat cycles were included. The main outcomes
measured were clinical pregnancy (CP) and live birth (LB) correlation to serum LH. Forward
multivariate stepwise regression analysis was applied, and other statistical tests were used as
appropriate.
Results: There was non significant correlation between basal serum LH and CP and LB in the
polycystic ovary syndrome group (R2 = 0.02, F = 1.7 and P = 0.76) (R2 = 0.01, F = 2.6 and P = 0.77)
respectively after adjusting for age, BMI, day of oocyte retrieval, starting dose, total dose of
stimulation, type of gonadotrophin used, number of oocytes retrieved, fertilization rate and
number of embryos transferred. Other aetiological causes group there was similarly non significant
correlation between basal serum LH and CP (R2 = 0.05, F = 13.1 and P = 0.66), nor for LB (R2 =
0.007, F = 4.5 and P = 0.9).
Conclusion: Early follicular serum LH measurements in the 6 months before IVF/ICSI treatment
cycle did not correlate with the clinical pregnancy or the live birth rate.
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Background
Controversy and debate still exist in defining ovarian
reserve, methods of testing, and its value in general fertil-
ity assessment and in assisted reproduction technology
(ART) [1-3].
Age is the most consistent variable that affects fertility
potential. Other tests for measuring ovarian reserve or pre-
dicting outcome of fertility treatments have been incon-
sistent in their prediction [1,2]. Basal (day 1–4 of the
follicular phase menstrual cycle) serum follicular stimu-
lating hormone (FSH) measurement, has been histori-
cally used as a predictor of ovarian reserve ART [4-6]
because of lower cost and ease of measurement. Women
with normal basal FSH and luteinising hormone (LH) lev-
els and those with a high LH: FSH ratio behaves as "nor-
mal "and" high" responders respectively, and classically
will have adequate number of mature oocytes available
for fertilization following standard ovarian stimulation
[6-8]. Patients with high FSH may respond poorly to
standard ovarian stimulation both in terms of oocyte
numbers and outcome of treatment [4,7].
Basal serum LH is measured as part of routine assessment
of subfertile women prior to ART [9]. Till recently serum
LH levels has been considered to be essential in the diag-
nosis of polycystic ovary syndrome (PCOS). The Rotter-
dam ESHRE/ASRM- Sponsored PCOS consensus
workshop group has recommended removal of LH meas-
urement from the new revised criteria for PCOS [10,11].
It was suggested that basal serum LH could predict ovarian
response to controlled ovarian hyperstimulation (COH)
[12-14]. Others did not confirm the value of measuring
serum basal LH in determining ovarian reserve or the clin-
ical outcome of ART [15]. The aim of this study is to deter-
mine the correlation between basal serum LH and clinical
pregnancy (CP) and live birth (LB) of consecutive and first
cycle IVF and ICSI.
Materials and methods
Data from 1333 consecutive cycles of IVF ± ICSI per-
formed in our centre were evaluated. The data were
extracted from a computer database. Serum FSH, LH, and
estradiol (E2) were measured in the early follicular phase
(day 1–4) within six months of the start of each treatment
cycle. As a rising serum E2 is associated with a drop in the
pituitary FSH and LH levels [16], these hormones were
reassessed on typically day 1 or 2 of the next cycle, when
the serum E2 levels were above 200 pmol/L. When serum
E2 level were <200 pmol/L, gonadotrophin levels were
considered to represents a true basal value [4,16]. In cases
of amenorrhea or oligomenorrhea withdrawal bleeding
was induced using medroxy progesterone acetate 5 mg
twice daily for five days followed by measuring serum
FSH, LH and E2 on day 2–4.
The long down regulation GnRH agonist protocol was
employed in all cycles. Luteal phase down regulation was
used except in cases with oligomenorrhea and irregular
cycles where the start day was on day two of cycle, of nat-
ural or induced period (follicular phase down regulation).
Pituitary down-regulation was achieved by buserelin 300
micrograms nasal inhalation 8 hourly, nafarelin 400
micrograms nasal inhalation 12 hourly or buserelin 500
micrograms daily by subcutaneous injection. The dose
was reduced by 50% when down regulation was con-
firmed. COH was achieved by daily injection of gonado-
trophins commencing at least two weeks later, after
confirming full down-regulation by means of the absence
of follicular activity, endometrial proliferation <5 mm or
cyst formation at baseline ultrasound scan.
The gonadotrophin, used for controlled ovarian hyper-
stimulation (COH) was recombinant FSH (r-FSH) or
human menopausal gonadotrophin (HMG) depending
on the availability and cost [17,18]. The variables used to
determine the gonadotrophin-starting dose were age,
body mass index (BMI), previous response to COH and
basal serum FSH level [19]. Neither the basal serum LH
nor the FSH: LH ratio was a variable to guide the COH. In
brief, the dose used in the COH protocols was: 110 IU/day
if < 30 years of age, 150 IU/day if 30–34 years of age, 225
IU/day if 35–38 years of age and 300 IU/day if the woman
age is above 38. If the basal FSH level was >9.9 IU/L, the
dose was increased by 50%. If BMI >30 (excluding poly-
cystic ovary) the dose was increased by 50%.
Human chorionic gonadotrophin (hCG) 10,000 iu was
administered when 3 or more follicles were greater than
18 mm in diameter and endometrial thickness of > 8 mm
with triple line/grade B development and occasionally "A"
grade. A cycle was abandoned if there were less than 3 fol-
licles, ≥ 14 mm of diameter, seen on ultrasound after 10
to 12 days of gonadotrophin stimulation.
Oocyte retrieval was done under intravenous sedation
using pethidine and midazolam according to the patient
response. Povidone iodine in aqueous solution was used
to clean vagina and then thoroughly washed with sterile
water to clean all traces of the iodine. Aspiration was
achieved using double lumen needle using hepernized
saline as a flushing medium. Aspiration pump pressure
was set around 100 mm Hg.
Oocytes were evaluated for evidence of normal fertiliza-
tion (2 distinct pronuclei) 18 hours after insemination.
Embryos of day 2 (4 cell stage) or day 3 (eight cell stage)
of high quality were transferred. Grading was according toReproductive Biology and Endocrinology 2007, 5:32 http://www.rbej.com/content/5/1/32
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number of blastomeres and degree of fragmentation. Soft
Wallace transfer catheter was used but if difficulties
encountered to negotiate the internal cervical os it was
changed to the stiffer Frydman catheter. Embryos were
transferred on day 2 after oocyte retrieval, except after Fri-
day's oocytes retrievals when they may be transferred on
day 3.
Luteal support was given in the form of progesterone pes-
saries 400 mg 12 hourly from day of egg collection for 17
days. Pregnancy test performed 14 days after embryo
transfer (ET). If the test is positive an ultrasound scan was
arranged 2–3 weeks later to confirm viability and exclude
multiple pregnancy. The use of progesterone pessaries
continue in pregnant patients until eight weeks gestation.
Clinical pregnancy was defined as ultrasonographic con-
firmation of an intrauterine gestation sac with fetal heart
movements four to five weeks following ET. A non-clini-
cal pregnancy was defined as a positive serum or urine
βhCG test, but no fetal heart activity detected on vaginal
ultrasound. A miscarriage was defined as a CP that ended
before 24 weeks. A live birth was defined as the delivery of
at least one viable infant. Twins and triplets were counted
as one LB.
Patient with hypothalamic hypogonadism and those
undergoing COH for ovum donation program or embryo/
oocyte cryopreservation prior to chemotherapy were not
included in the study. The upper age limit for starting an
IVF cycle in our centre was 45 years.
To study the effect of low basal serum LH (<3 IU/L) and
high level (>8 IU/L), the study group was divided into 3
groups based on the basal serum LH level: Group I: ≤ 3 IU/
L, Group II: 3.1–7.9 IU/L, Group III: ≥ 8 IU/L. These values
were used to be consistent with previously published
reports [12,13,20].
Hormonal assay
Measurements were performed by a Bayer immuno-1
automated analyser (Bayer, Newbury, Bucks, UK). In our
hospital, we measure the serum LH level by calibrating to
the Second International Reference Preparation of the
WHO (2nd IRP 80/552). The sensitivity of the assay was
0.1 IU/L. The intra-assay and interassay coefficients of var-
iation were 5.5% and 6.7% respectively. Serum LH range
was 0.7 – 10 IU/L in the follicular phase.
Outcome measures
The main outcome measures were CP rate and LB rate.
Secondary outcome measured analysed included the total
dose of gonadotrophins, number of days of stimulation,
number of oocyte retrieved, fertilization rate, numbers of
embryos available, number of cycles requiring coasting
for ≥ 2 days, and miscarriage rate.
Statistical analysis
A Kolmogorov-Smirnov test was used to assess all varia-
bles for normality. Since the distribution of LH levels was
not parametric, comparison of LH levels in between the
groups of the different outcome measures (CP, miscar-
riage and LB) was done using a Mann-Whitney U test.
Comparison of number of oocytes, fertilization rate and
number of embryos between the three groups of basal
serum LH was calculated by Kruskal Wallis analysis of var-
iance. When the overall effect was significant, multiple
Mann Whitney U tests were used to determine the source
of significance. For comparing nominal data, Chi square
(χ2) test was performed with Yates correction where
appropriate. A probability value (P value) < 0.05 was con-
sidered significant.
To diminish the effect of confounding variables the anal-
ysis was performed by aetiology specially considering the
effect of those with PCOS and other aetiology group using
forward multivariate stepwise regression analysis. Odds
ratio (OR) and confidence interval (CI) were used when-
ever appropriate. The power analysis was 82.8% in detect-
ing an LH difference of 2 IU/L assuming a population s =
12 IU/L. The a-error level was fixed at 0.05.
All statistical calculations were done using Microsoft Excel
version 7 and SPSS (Statistical Package for the Social Sci-
ence; SPSS Inc., Chicago, IL, USA).
Results
A total of 1333 consecutive IVF ± ICSI cycles were
included in the study. Table 1 and 2 describe the demo-
graphic characteristics of the women included. Total dose
of gonadotrophin used ranged between 1000–8300 IU
with median 2800 IU while total days of stimulation
ranged between 9–23 days with a median of 15 days.
Three embryos were transferred in 13% of cases, while
Table 1: Demographic characteristics of study group
Number 1333
Age (years) 34 (18–45)
BMI 24 (19–37)
Basal LH level (IU/L) 5.3 (0.7–27.6)
Causes of infertility (%)
Male 43
Tubal 21
Endometriosis 5.6
PCOS 9
Unexplained 21.4
Abandon cycles (%) 3.6
BMI = body mass index
Values of age, BMI and LH level are given as median (range).Reproductive Biology and Endocrinology 2007, 5:32 http://www.rbej.com/content/5/1/32
Page 4 of 6
(page number not for citation purposes)
83% of cases had 2 embryos replaced in uterus and 4%
had one embryo replaced.
48 cycles (3.6%) did not go through oocyte retrieval due
to low response with median basal serum LH 5.3 IU/L,
which was not different from those who underwent
oocyte retrieval 5.3 IU/L (P = 0.9). Nine hundreds and
sixty four (72.3%) patients had first IVF/ICSI cycles. This
subgroup basal serum LH ranged from 0.7 to 27.6 IU/L
(median 5.2). Multivariable logistic regression anlysis of
the entire study group shows that age (OR 0.942, 95% CI
0.917–0.968, P < 0.001) and basal serum FSH (OR
0.920,95% CI 0.876–0.965, P = 0.001) were significantly
and independently related to whether or not there was
pregnancy. Similar analysis showed that age (OR 0.940,
95% CI 0.914–0.968, P < 0.001) and basal serum FSH
(OR 0.934,95% CI 0.887–0.984, P = 0.01) was signifi-
cantly and independently related to whether or not there
was a live birth following IVF and ICSI. Analysis of basal
serum LH did not show a significant relation to pregnancy
(OR 0.975, 95% CI 0.931–1.02, P = 0.267) nor to LB (OR
0.987, 95%CI 0.941–1.036. P = 0.594).
We separately analysed the PCOS group. The range of the
basal serum LH in this subgroup was 1.5 to 27.6 (median
5.8). Forward multivariate stepwise regression analysis
was performed to determine factors that were significantly
and independently associated with variation in the clini-
cal outcome. The dependant variable was the CP and LB.
For the PCOS group there was non significant correlation
between basal serum LH and CP (R2 = 0.02, F = 1.7 and P=
0.76) or to LB (R2 = 0.01, F = 2.6 and P = 0.77) after adjust-
ing for age, BMI, day of oocyte retrieval, starting dose,
total dose of stimulation, type of gonadotrophin used,
number of oocytes retrieved, fertilization rate and number
of embryos transferred. Applying the same principle for
other aetiological causes group there was non significant
correlation between basal serum LH and CP (R2 = 0.05, F
= 13.1 and P = 0.66), nor for LB (R2 = 0.007, F = 4.5 and P
= 0.9).
When the cycles were grouped by the basal serum LH
range (group I ≤ 3 IU/L, group II 3.1–7.9 IU/L, and group
III ≥ 8 IU/L) and applying the Kruskal-Wallis ANOVA test
there was no statistical significance difference between the
three groups in terms of CP rate (P = 0.4), miscarriage rate
(P = 0.8) or LB rate (P = 0.2) (Table 3). Multiple Mann-
Whitney U test showed that the cycle with highest number
of oocytes, fertilization and embryos was in the group III.
Discussion
In this study we have investigated the relationship
between basal serum LH and ART outcome in a large
number (1333) of consecutive and first (964) cycles IVF
and ICSI cycles. Multivariate stepwise regression analysis
identified that measuring basal serum LH did no correlate
with the outcome of ART cycles in terms of CP rate, mis-
carriage rate or LB rate. But we have identified by multivar-
iable regression analysis that younger women (age) and
the lower the basal serum FSH, the more likely women are
to have live birth following IVF/ICSI. When the cycles
were grouped by serum LH values to identify if low and
high levels influenced the CP, miscarriage or the LB we
noticed no statistical difference in the clinical outcome.
Jurema et al (2003) in their study on cycles using GnRH
antagonists [15] found that baseline FSH and E2, but not
LH were significantly lower in cycles with pregnancy and
as a single hormone FSH demonstrated the highest accu-
racy for predicting IVF outcome in GnRH agonist cycles
compared to LH or E2. Our analysis confirms that in cycles
using GnRH agonist down regulation basal LH has no cor-
relation to ART outcome.
Mukherjee et al. [13] suggested that an elevated day 3
FSH: LH ratio >3.6, in the presence of a normal day 3 FSH
is predictive of a poor response to ovarian stimulation. In
their study performed on 74 cycles, they suggested that a
cycle day 3 serum LH value <3 IU/L was, predictive of a
poor response to ovarian stimulation [13]. Similarly Noci
et al. [12] stated that low basal serum LH values < 3 IU/L,
predict reduced response to ovarian stimulation as judged
by decrease peak E2 and a lower number of preovulatory
follicles in ovulation induction cycles. It was speculated
that when early follicular LH levels are low there may be
reduced activity of one or more of the known ovarian reg-
ulators (i.e., steroids or proteins such as inhbin, activin,
follistin or insulin-like growth factors), which can influ-
ence follicular growth through actions by autocrine or
paracrine routes [12]. Later Noci et al. [20] updated their
findings on 249 IVF cycles, when GnRH agonist desensiti-
sation was used and stimulation with HP-FSH. They
found no difference in ovarian response, but noted that
high dose of FSH dose was required in those with serum
LH <3 IU/L. However when we sub grouped our study
population by serum LH levels similar to the above stud-
ies a statistical difference was found in cycles with basal
Table 2: Characteristics of first cycle treatment
Number 964
Age (years) 33 (19–45)
BMI 25 (19–36)
Basal LH level (IU/L) 5.7 (0.7–27.6)
Causes of infertility (%)
Male 47.2
Tubal 19.4
Endometriosis 6.7
PCOS 8.4
Unexplained 28.3
Abandon cycles (%) 4
BMI = body mass index
Value of age, BMI and LH level is given as median (range).Reproductive Biology and Endocrinology 2007, 5:32 http://www.rbej.com/content/5/1/32
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serum LH ≥ 8 IU/L in relation to number of oocytes
retrieved, fertilisation and total number of embryos avail-
able. Although this was statistically significant, the differ-
ence is of doubtful clinical value representing only an
increase of one oocyte retrieved and one extra embryo
available between those with <8 and those ≥ 8 IU/L. But
essentially the main outcome measures of CP, miscarriage
and LB were similar in between the groups. Others have
reported that patients undergoing ART with low basal LH
levels (< 3 IU/L) did not differ significantly from controls
in terms of response to COH, but there was a clear trend
toward poorer implantation and CP rates [14]. We have
noticed the contrary, in that women with the lowest basal
serum LH (<3 IU/L) have a tendency to higher LB, all be it
not statistically significant.
Several explanations may be proposed for what we have
observed. Although LH remains in the circulation after
pituitary desensitisation following the use of GnRHa it is
of low biological value, [21], but still can provide enough
derive for adequate steriodogenesis in the developing fol-
licles. It has been demonstrated that in a GnRHa down-
regulated IVF patients, the response to FSH is independent
of serum LH levels at the time of starting FSH administra-
tion or on the day of hCG administration [22,23]. A
recent meta-analysis has confirmed that measuring serum
LH during ovarian stimulation in ART cycles is at present
of no value [24]. We measured basal serum LH between
days 1–4 of non stimulated menstrual cycle as it coincides
with measurements of serum FSH and E2.  Measuring
serum LH in a different day in the menstrual cycle espe-
cially in oligomenorrheic women may provide different
results [25].
There is considerable debate about the value of supple-
menting LH in COH for ART. While van Wely et al. [18]
in a meta-analysis concluded that the use of hMG resulted
in higher CP rates than did the use of r-FSH in IVF/ICSI
cycles after GnRH agonist down-regulation in a long pro-
tocol, Al-Inany et al. [17] showed no evidence of clinical
superiority in CP rate for rFSH over different urinary-
derived FSH gonadotrophins. They suggested additional
factors should be considered when choosing a gonado-
trophin regimen, including the cost, patient acceptability,
safety and drug availability [18]. We have used during
COH, hMG or r-FSH based on availability and cost as the
evidence so far available indicate no difference in their
efficacy.
Embryo quality has an important correlation with the out-
come of IVF treatment [26] which we acknowledge. How-
ever, it remains subjective, with possible inner observer
variation and does not provide means to identify une-
quivocally embryos with enhanced implantation poten-
tial. So to avoid the bias embryo grading was not included
in the multivariate stepwise regression analysis.
Antral follicle count (AC) and serum anti müllarian hor-
mone (AMH) have been suggested as more predictive of
ART than basal FSH [27], but their predictive value is still
not universally accepted [1]. Both these tests still require
large studies and more stringent evaluation because of
cost and need for more expert assessment and definition
in regard to AC [1-3].
Conclusion
This study shows that the basal serum LH has no useful
predictive value for IVF/ICSI clinical pregnancy and live
birth outcome. We suggest that serum LH measurement
can be dropped from tests prior to ART and the measure-
ment of other may be more predictive cost effective tests
used. The value of measuring serum LH in routine fertility
and endocrinological conditions remain to be confirmed
by further studies.
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Table 3: Ovarian stimulation response and IVF/ICSI outcome according to basal serum LH
Oocytes retrieval cycle Fertilization rate % CP Misc LB
Group I
LH = 3 IU/L
N = 160 N = 59 N = 6 N = 53
10 (2–22) 56.3 (0–100) 36.8% 10.1% 33.1%
Group II
LH 3.1–7.9 IU/L
N = 960 N = 291 N = 51 N = 240
10 (0–38) 55.6 (0–100) 30.3% 17.5% 25%
Group III
LH ≥ 8.0 IU/L
N = 213 N = 77 N = 16 N = 61
11 (0–29) 56.3 (0–100) 36.2% 20.7% 28.6%
P value <0.05 <0.05 NS NS NS
CP = clinical pregnancy, Misc = miscarriage, LB = live birth, N = number, NS = not significant
Values are given as median (range) or percentage.
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